Topics

Teva Sues FDA For Excluding Copaxone From BLA Transition

09:09 EDT 26 Mar 2020 | SCRIP

Teva and US FDA disagree over whether Copaxone is a protein. While generics are already on the market, Teva wants...

      

Related Stories

 

Original Article: Teva Sues FDA For Excluding Copaxone From BLA Transition

NEXT ARTICLE

More From BioPortfolio on "Teva Sues FDA For Excluding Copaxone From BLA Transition"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...